Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Venous Thromboembolism 1 TP53 Y220C Mutation 1 Sarcoma, Synovial 1 Sarcoma, Alveolar Soft Part 1 Sarcoma 1 Pulmonary Embolism 1 Prostatic Neoplasms, Castration-Resistant 1 Peripheral Nervous System Diseases 1 Neoplasms 1 Liver Cirrhosis 1 Leiomyosarcoma 1 Healthy Participants 1 Healthy Adult Participants 1 Endometrial Neoplasms 1 Drug-drug Interaction,SHR3680 1 Cardiotoxicity 1 Breast Neoplasms 1 Advanced Solid Malignancies 1

Interventions

Fulvestrant 125 Trastuzumab 114 Paclitaxel 113 Letrozole 108 pembrolizumab 79 pertuzumab 75 palbociclib 75 Capecitabine 72 Anastrozole 72 Cyclophosphamide 70 Carboplatin 67 abemaciclib 64 exemestane 63 Tamoxifen 63 ribociclib 60 trastuzumab deruxtecan 57 Surveys and Questionnaires 51 Specimen Handling 50 Radiotherapy 49 Docetaxel 49 Magnetic Resonance Spectroscopy 48 Blood Specimen Collection 40 olaparib 39 Standard of Care 36 Biopsy 33 sacituzumab govitecan 31 130-nm albumin-bound paclitaxel 31 Doxorubicin 30 Exercise 29 eribulin 27

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Neoplasms × Rosuvastatin Calcium × 1 year × Clear all

NCT07254221 2025-12-10

ROSUBREAST

Shiraz University of Medical Sciences

Phase 4 Not yet recruiting

Breast Neoplasms, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡